Simplify Logo

Full-Time

Senior Scientist

Analytical Development, Potency Assays

Posted on 7/18/2024

Vor Bio

Vor Bio

51-200 employees

Develops targeted therapies for blood cancers

Hardware
Biotechnology
Healthcare

Expert

Cambridge, MA, USA

Category
Computational Biology
Biology & Biotech
Requirements
  • Ph.D. in cell biology/immunology or related scientific discipline with 5+ years relevant industry/academic experience; or MS with 10+ years' experience; or BS with 12+ years' experience
  • Experience managing direct reports is required
  • Extensive hands-on experience in HSPC and/or CAR-T cell therapy products is required
  • Extensive hands-on experience with cell line and primary cell culture is required
  • Experience in phenotypic and functional characterization of hematopoietic cells and immune cells using multi-color flow cytometry and other functional assays (proliferation, CFU, transplantation) is strongly preferred
  • Experience developing analytical assays in late-stage clinical development is strongly preferred
  • Excellent oral and written communication skills and demonstrated ability in presenting scientific results is strongly preferred
  • Strong problem-solving skills and proven ability to work both independently and in a team in a startup environment is desired
  • High attention to detail and demonstrated track record of consistently meeting deadlines in a dynamic, fast-paced environment
  • Experience in cell therapy process, product development and GMP manufacturing is a plus
Responsibilities
  • Independently plan, design, execute, analyze and troubleshoot experiments to improve the understanding of HSPC and CAR-T cell therapy products
  • Manage direct reports and collaborative efforts within the Process and Analytical Development group
  • Establish, optimize, and execute in vitro cell-based assays, including cytotoxic assays, CFU, and multi-color flow cytometry
  • Draft and review SOPs, reports, and assist in the preparation of CMC regulatory submissions
  • Plan and deliver results according to project timelines
  • Work collaboratively and communicates data within internal cross-function teams and external CRO; present scientific results at internal and external meetings/conferences

Vor Biopharma focuses on developing treatments for blood cancers, particularly Acute Myeloid Leukemia (AML). Their approach is designed to protect healthy cells while specifically targeting and eliminating cancerous cells. This method aims to improve the effectiveness of blood cancer treatments. Vor Biopharma serves patients with blood cancers, their caregivers, and medical professionals in hospitals and oncology centers. What sets Vor Biopharma apart from its competitors is its commitment to extensive research and development of novel therapies, supported by a team with significant experience in the biopharmaceutical field. The company generates revenue through partnerships with other pharmaceutical companies and licensing agreements, with the goal of commercializing their therapies after obtaining regulatory approval.

Company Stage

IPO

Total Funding

$267.8M

Headquarters

Cambridge, Massachusetts

Founded

2015

Growth & Insights
Headcount

6 month growth

0%

1 year growth

6%

2 year growth

44%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful transplantation of the first AML patient with Vor Bio’s investigational Trem-cel (VOR33) demonstrates promising clinical progress.
  • The recent $115.8 million funding round strengthens Vor Bio’s financial position, enabling further R&D and potential market expansion.
  • Strategic partnerships, such as the licensing agreement with Editas Medicine, enhance Vor Bio’s capabilities in gene editing and broaden its therapeutic pipeline.

What critics are saying

  • The highly specialized and competitive nature of the biopharmaceutical market requires continuous innovation and significant investment in R&D.
  • Regulatory hurdles and the lengthy approval process for new therapies can delay commercialization and revenue generation.

What makes Vor Bio unique

  • Vor Bio's unique approach of protecting healthy cells while targeting cancerous ones sets it apart in the competitive biopharmaceutical landscape.
  • The company's focus on Acute Myeloid Leukemia (AML) and its proprietary platform for gene-edited hematopoietic stem cell therapies provide a specialized niche.
  • Founded by a Pulitzer Prize-winning author and supported by a team of world-class leaders, Vor Bio leverages exceptional expertise and credibility in the biopharma sector.
INACTIVE